Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG|Designated|Prevention of rejection of pancreatic islet cell transplants." in comments (approximate match)

Showing 1 - 1 of 1 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

RUPLIZUMAB

562JQF15GN

Subunit 1 (447) Similarity Search Subunit 2 (447) Similarity Search Subunit 3 (218) Similarity Search Subunit 4 (218) Similarity Search

Sequence Search

Subunit 1 (447) Similarity Search Subunit 2 (447) Similarity Search Subunit 3 (218) Similarity Search Subunit 4 (218) Similarity Search

Status:

Investigational

Source:

NCT00001789: Phase 2 Interventional Completed Glomerulonephritis, Membranoproliferative

(1999)

Source URL:

https://clinicaltrials.gov/ct2/show/NCT00001789

Class:

PROTEIN

Protein

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1